Pubblicato il 11 gen 2019 Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers, Perampanel Data This week Neurology News Network covered the tentative approval granted by the FDA for Banner Life Sciences' NDA for a novel fumarate bioequivalent alternative for dimethyl fumarate as a treatment for relapsing multiple sclerosis, Empatica's Embrace smartband that was granted 510(k) device clearance by the FDA for use with pediatric patients with epilepsy aged 6 years and older, and new research that has identified a trio of biomarkers for detection of both mild cognitive impairment and Alzheimer disease in saliva samples. We also shared a clip from a recent conversation with Trevor Resnick, MD, pediatric epileptologist at Nicklaus Children's Hospital, who spoke about the encouraging results from the long-term seizure freedom data on perampanel that demonstrated its clinical impact for patients with secondarily generalized seizures.
